Allogene Therapeutics announced that Dr. David Chang will step down as CEO on June 30, 2026, after eight years leading the company, and remain on the board. Dr. Zachary Roberts, currently EVP of Research & Development and Chief Medical Officer, will become CEO and join the board on July 1, 2026. Roberts has driven key clinical advances, including the pivotal ALPHA3 trial for large B-cell lymphoma, and is expected to lead Allogene's next growth phase in allogeneic CAR T therapies. The leadership transition reflects a planned succession to continue innovation in off-the-shelf cell therapies for cancer and autoimmune diseases.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
Gooch & Housego, a UK-listed photonics company specializing in precision optics for aerospace and defence, has agreed to a £345.6 million takeover by US private equity firm Arlington Capital Partners. The offer values the company at a 41.3% premium t...
Aave DAO has proposed an innovative mobile app that integrates fiat currency deposits, self-custody, and decentralized finance (DeFi) lending in one platform. This app allows users to convert fiat to stablecoins and earn yields without needing extern...
Analysts expect Netflix to report $12.6 billion in revenue for Q2 and $51.3 billion for the full year 2026. The operating margin forecast has been revised down from 33% to 32% due to anticipated higher expenses, with an expected operating profit of $...
